-
Thematic Analysis
China Retaliates Against US Tariffs - New US Administration
Within the first 100 days of the current US Administration, there has been a clear shift toward more protectionist trade policy. The 47th US President has implemented a series of tariff measures aimed at reducing the trade deficit. To date, key outcomes have included: • Imposition of a 10% global baseline tariff • Introduction of a reciprocal tariff framework • Significant tariffs on strategic sectors such as steel, aluminum, and automotive • Heightened tensions between the US and China
-
Thematic Analysis
Looming Tariffs on Pharma Timelines - New US Administration
Within the first 100 days of the current US Administration, there has been a clear shift toward more protectionist trade policy. The 47th US President has implemented a series of tariff measures aimed at reducing the trade deficit. To date, key outcomes have included: • Imposition of a 10% global baseline tariff • Introduction of a reciprocal tariff framework • Significant tariffs on strategic sectors such as steel, aluminum, and automotive • Heightened tensions between the US and China
-
Sector Analysis
Post-Traumatic Stress Disorder (PTSD) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2034
This report covers the 7MM and provides an Excel-based forecast model for the Post-Traumatic Stress Disorder market through 2034. Trauma-based psychotherapy is widely considered to be the first line of therapeutic intervention for PTSD patients, with pharmacotherapy often used as an adjunct to psychotherapy. Only two drugs, both SSRIs, have been approved by the FDA for the treatment of PTSD: Zoloft (sertraline) and Paxil (paroxetine). The central issue with pharmacotherapy in PTSD is a lack of efficacy of available treatments....
-
Sector Analysis
Idiopathic Hypersomnia (IH) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Idiopathic Hypersomnia Therapeutics. - GlobalData epidemiologists estimate that there were 282,225 diagnosed prevalent cases of Idiopathic Hypersomnia (IH) in 2024, which is expected to increase slightly to 288,583 diagnosed prevalent cases by 2029. - Currently, the IH market has only one approved symptomatic relief therapy, and no disease-modifying therapies are available in the market. - The IH pipeline holds 11 molecules, with no assets in the...
-
Sector Analysis
Narcolepsy Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Narcolepsy Therapeutics. - GlobalData epidemiologists estimate that there were 735,082 diagnosed prevalent cases of Narcolepsy in 2024, which is expected to increase slightly to 761,297 diagnosed prevalent cases by 2029. - Currently, the narcolepsy market is saturated with generic drugs, and few innovative therapies are available in the market. - The narcolepsy pipeline holds 28 molecules, with no assets in the pre-registration stage, five assets in...
-
Sector Analysis
Chronic Obstructive Pulmonary Disease (COPD) in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033
This report covers the 7 major markets and provides an Excel-based forecast model for the Chronic Obstructive Pulmonary Disease (COPD) market through 2033. COPD is a progressive lung disease characterized by an abnormal inflammatory response and airflow obstruction that is not fully reversible. According to GOLD 2023, COPD has been defined as a heterogenous lung condition that is characterized by chronic symptoms (dyspnea, cough, sputum production, and/or exacerbations due to abnormalities of the airways [bronchitis, bronchiolitis] and/or alveoli [emphysema]) that...
-
Sector Analysis
Chronic Obstructive Pulmonary Disease (COPD) in 68 Markets - Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Chronic Obstructive Pulmonary Disease (COPD) market through 2033. GlobalData estimated that drug sales for COPD in 2023 were approximately $11.6 billion across the 7MM. The US market makes up the majority of total global sales, contributing $8.6 billion (74.1%) due to the large COPD prevalent population, combined with the high price of medication in the country. GlobalData anticipates that the COPD market will grow to...
-
Thematic Analysis
Transformational Power of Genomics in Pharma: Strategic Intelligence
Accelerating technologies within the genomics landscape: Several advancements in the pharmaceutical industry have enabled the field of genomics to expand, with researchers innovating new means of therapy for patients with a wide variety of diseases, subsequently enabling in-depth insights to be generated within the genomics landscape. Genomics therapies are paving the way for novel treatments that address the root cause of diseases, allowing additional resources to be allocated for efficient precision and personalized medicine therapies for the treatment of rare...
-
Sector Analysis
Bronchiectasis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033
This report covers the 8MM (US, France, Germany, Italy, Spain, UK, Japan, China) and provides an Excel-based forecast model for the bronchiectasis market through 2033. Report deliverables include a PowerPoint report and an Excel-based forecast model. Bronchiectasis, which has been given diagnostic code of J47.9 from the International Classification of Diseases, Tenth Edition (ICD-10), is defined by damage to the bronchi, causing abnormal dilation and scarring. The airways become inflamed with thick mucus that is difficult to clear, which build-up...
-
Sector Analysis
Current Trends in Targeted Therapies in Non-Small Cell Lung Cancer (NSCLC) – Market Drivers and Challenges
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases There are currently ten actionable genomic alterations (AGAs) that are addressed by targeted therapy agents across multiple lines of therapy. Patients who did not undergo genetic testing or tested negative for AGAs, receive immunotherapy agents depending on their PD-L1 status. Chemotherapy works as salvage therapy for late-line recurrent/relapsed patients. - Targeted therapy in NSCLC is a highly competitive...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.